| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
|
N Engl J Med
|
2013
|
16.33
|
|
2
|
Cytogenetics in acute leukemia.
|
Blood Rev
|
2004
|
9.99
|
|
3
|
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
|
N Engl J Med
|
2014
|
5.37
|
|
4
|
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
|
Blood
|
2010
|
5.11
|
|
5
|
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.
|
Nat Genet
|
2009
|
4.35
|
|
6
|
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.
|
J Clin Oncol
|
2012
|
4.34
|
|
7
|
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.
|
J Clin Oncol
|
2009
|
4.20
|
|
8
|
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
|
Blood
|
2006
|
3.91
|
|
9
|
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
|
Proc Natl Acad Sci U S A
|
2010
|
3.86
|
|
10
|
Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Blood
|
2007
|
3.79
|
|
11
|
The genomic landscape of hypodiploid acute lymphoblastic leukemia.
|
Nat Genet
|
2013
|
3.43
|
|
12
|
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.
|
Blood
|
2006
|
3.17
|
|
13
|
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
|
Blood
|
2006
|
3.16
|
|
14
|
Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.
|
Blood
|
2007
|
3.11
|
|
15
|
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
|
J Clin Oncol
|
2005
|
3.05
|
|
16
|
Clinical implications of FLT3 mutations in pediatric AML.
|
Blood
|
2006
|
2.72
|
|
17
|
Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
|
Blood
|
2003
|
2.65
|
|
18
|
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
|
J Clin Oncol
|
2007
|
2.64
|
|
19
|
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.
|
Blood
|
2009
|
2.57
|
|
20
|
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.
|
Blood
|
2004
|
2.39
|
|
21
|
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
|
Blood
|
2009
|
2.36
|
|
22
|
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
|
J Clin Oncol
|
2009
|
2.34
|
|
23
|
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.
|
J Clin Oncol
|
2011
|
2.26
|
|
24
|
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
|
Blood
|
2008
|
2.22
|
|
25
|
Racial and ethnic differences in survival of children with acute lymphoblastic leukemia.
|
Blood
|
2002
|
2.17
|
|
26
|
Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group.
|
Blood
|
2006
|
2.05
|
|
27
|
Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation.
|
Cancer Cell
|
2012
|
2.01
|
|
28
|
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.
|
Blood
|
2009
|
1.83
|
|
29
|
Update on late relapse of germ cell tumor: a clinical and molecular analysis.
|
J Clin Oncol
|
2003
|
1.70
|
|
30
|
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.
|
Cancer
|
2014
|
1.68
|
|
31
|
Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
|
Blood
|
2002
|
1.68
|
|
32
|
Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.
|
J Clin Oncol
|
2009
|
1.58
|
|
33
|
Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience.
|
Int J Oncol
|
2008
|
1.57
|
|
34
|
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.
|
J Clin Oncol
|
2012
|
1.56
|
|
35
|
Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia.
|
Blood
|
2007
|
1.56
|
|
36
|
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.
|
Cancer Cell
|
2012
|
1.52
|
|
37
|
Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets.
|
Cancer Res
|
2004
|
1.52
|
|
38
|
Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.
|
Blood
|
2006
|
1.48
|
|
39
|
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
|
Blood
|
2010
|
1.44
|
|
40
|
Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children's oncology group.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
1.39
|
|
41
|
Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Blood
|
2011
|
1.39
|
|
42
|
Precancerous stem cells have the potential for both benign and malignant differentiation.
|
PLoS One
|
2007
|
1.36
|
|
43
|
Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.
|
Br J Haematol
|
2008
|
1.34
|
|
44
|
Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881.
|
J Clin Oncol
|
2003
|
1.27
|
|
45
|
WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group.
|
J Clin Oncol
|
2010
|
1.26
|
|
46
|
Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study.
|
Blood
|
2011
|
1.25
|
|
47
|
Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.
|
Blood
|
2011
|
1.25
|
|
48
|
Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study.
|
Blood
|
2007
|
1.23
|
|
49
|
Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study.
|
Blood
|
2005
|
1.20
|
|
50
|
Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.
|
Cancer Res
|
2003
|
1.19
|
|
51
|
Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.
|
Blood
|
2010
|
1.17
|
|
52
|
A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism.
|
Blood
|
2004
|
1.16
|
|
53
|
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
|
Blood
|
2010
|
1.16
|
|
54
|
Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias.
|
Blood
|
2012
|
1.13
|
|
55
|
Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group.
|
J Clin Oncol
|
2010
|
1.13
|
|
56
|
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.
|
J Clin Oncol
|
2004
|
1.11
|
|
57
|
Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells.
|
AAPS J
|
2011
|
1.11
|
|
58
|
Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952.
|
Pediatr Blood Cancer
|
2005
|
1.09
|
|
59
|
Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability.
|
Cancer Res
|
2007
|
1.08
|
|
60
|
Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate.
|
Cancer Genet
|
2011
|
1.06
|
|
61
|
Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease.
|
PLoS One
|
2013
|
1.06
|
|
62
|
Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia.
|
Genes Chromosomes Cancer
|
2005
|
1.05
|
|
63
|
Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report.
|
Biol Blood Marrow Transplant
|
2007
|
1.05
|
|
64
|
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2011
|
1.03
|
|
65
|
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.
|
Blood
|
2008
|
1.00
|
|
66
|
Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.
|
Blood
|
2013
|
0.99
|
|
67
|
Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.
|
Blood
|
2013
|
0.99
|
|
68
|
Acute lymphoblastic leukemia with hypereosinophilia: report of a case with 5q deletion and review of the literature.
|
Pediatr Dev Pathol
|
2004
|
0.98
|
|
69
|
Genetic variants modify susceptibility to leukemia in infants: a Children's Oncology Group report.
|
Pediatr Blood Cancer
|
2012
|
0.97
|
|
70
|
Exposure to medical test irradiation and acute leukemia among children with Down syndrome: a report from the Children's Oncology Group.
|
Pediatrics
|
2006
|
0.96
|
|
71
|
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
|
Leuk Lymphoma
|
2012
|
0.96
|
|
72
|
Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: a report from Children's Cancer Group Study CCG-E08.
|
J Pediatr Hematol Oncol
|
2004
|
0.96
|
|
73
|
Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08.
|
Cancer Genet Cytogenet
|
2007
|
0.93
|
|
74
|
An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961.
|
Br J Haematol
|
2009
|
0.92
|
|
75
|
Common chromosome fragile sites in human and murine epithelial cells and FHIT/FRA3B loss-induced global genome instability.
|
Genes Chromosomes Cancer
|
2013
|
0.92
|
|
76
|
Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.
|
Br J Haematol
|
2012
|
0.91
|
|
77
|
Infant leukemia and parental infertility or its treatment: a Children's Oncology Group report.
|
Hum Reprod
|
2010
|
0.91
|
|
78
|
Periconceptional vitamin useand leukemia risk in children with Down syndrome: a Children's Oncology Group study.
|
Cancer
|
2005
|
0.90
|
|
79
|
Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia.
|
Leuk Res
|
2007
|
0.88
|
|
80
|
Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2013
|
0.87
|
|
81
|
AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.
|
Blood
|
2011
|
0.86
|
|
82
|
Maternal prenatal cigarette, alcohol and illicit drug use and risk of infant leukaemia: a report from the Children's Oncology Group.
|
Paediatr Perinat Epidemiol
|
2011
|
0.85
|
|
83
|
BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2013
|
0.85
|
|
84
|
Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium.
|
Cancer Genet Cytogenet
|
2010
|
0.83
|
|
85
|
Pediatric acute lymphoblastic leukemia with a t(8;14)(q11.2;q32): B-cell disease with a high proportion of Down syndrome: a Children's Oncology Group study.
|
Cancer Genet
|
2012
|
0.83
|
|
86
|
Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease.
|
Br J Haematol
|
2009
|
0.83
|
|
87
|
Characterization of gains, losses, and regional amplification in testicular germ cell tumor cell lines by comparative genomic hybridization.
|
Cancer Genet Cytogenet
|
2004
|
0.82
|
|
88
|
Therapy-related pro-B cell acute lymphoblastic leukemia: report of two patients with MLL amplification.
|
Cancer Genet
|
2012
|
0.82
|
|
89
|
Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2011
|
0.81
|
|
90
|
Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).
|
Pediatr Blood Cancer
|
2014
|
0.80
|
|
91
|
MLL gene rearrangements in infant leukemia vary with age at diagnosis and selected demographic factors: a Children's Oncology Group (COG) study.
|
Pediatr Blood Cancer
|
2011
|
0.80
|
|
92
|
Maternal exposure to household chemicals and risk of infant leukemia: a report from the Children's Oncology Group.
|
Cancer Causes Control
|
2011
|
0.80
|
|
93
|
Telomere length and telomerase reverse transcriptase gene copy number in patients with papillary thyroid carcinoma.
|
J Clin Endocrinol Metab
|
2011
|
0.79
|
|
94
|
Characterization of the role of Fhit in suppression of DNA damage.
|
Adv Biol Regul
|
2012
|
0.79
|
|
95
|
Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961.
|
Blood
|
2006
|
0.79
|
|
96
|
Congenital abnormalities and acute leukemia among children with Down syndrome: a Children's Oncology Group study.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
0.78
|
|
97
|
Vitamin supplement use among children with Down's syndrome and risk of leukaemia: a Children's Oncology Group (COG) study.
|
Paediatr Perinat Epidemiol
|
2008
|
0.76
|
|
98
|
A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1.
|
J Pediatr Hematol Oncol
|
2016
|
0.75
|
|
99
|
Primary follicular lymphoma of the testis in children and adolescents.
|
J Pediatr Hematol Oncol
|
2012
|
0.75
|
|
100
|
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.
|
Leuk Lymphoma
|
2013
|
0.75
|
|
101
|
Novel Clonal t(2;4) (q23;p14) Secondary Cytogenetic Abnormality in a Primary Myxoid Liposarcoma.
|
Appl Immunohistochem Mol Morphol
|
2015
|
0.75
|
|
102
|
Complex secondary chromosome abnormalities in advanced stage anaplastic large cell lymphoma of children and adolescents: a report from CCG-E08.
|
Cancer Genet Cytogenet
|
2006
|
0.75
|
|
103
|
Novel Clonal der(9)t(5;9)(q31;q34) Cytogenetic Translocation in a Giant Cell Tumor of Bone.
|
Appl Immunohistochem Mol Morphol
|
2015
|
0.75
|